ABSTRACT-L-Dopa is a potentiator for presynaptic ~-adrenoceptors. We studied whether L-dopa poten tiates the activities of other presynaptic receptors to modulate the evoked noradrenaline (NA) release in rat hypothalamic slices. UK14304 (0.1-1 riM), a selective a2-agonist, concentration-dependently inhibited NA release. Noneffective 10 PM L-dopa potentiated the UK14304-induced inhibition. This potentiation was selectively antagonized by 1 nM L-dopa methyl ester, a competitive L-dopa antagonist, while yohimbine an tagonized both the inhibition by UK14304 alone and its potentiation by L-dopa. However, 10 PM L-dopa produced no effect on angiotensin II (0.1-1 nM)-induced facilitation. L-Dopa potentiates activities of presynaptic ~ and a2-adrenoceptors but not those of angiotensin II receptors on rat hypothalamic NA neurons.
L-Dopa is believed to be an inert amino acid that exerts its actions through its conversion to dopamine (DA) by aromatic L-amino acid decarboxylase (AADC). Contrary to this generally accepted idea, we found that endogenous L-dopa is released in a transmitter-like manner from in vitro and in vivo rat striata (1) (2) (3) . On the other hand, even under essentially complete inhibition of AADC, nanomolar concentrations of L-dopa stereo selectively facilitate via presynaptic (3-adrenoceptors the impulse evoked release of noradrenaline (NA) and DA from rat brain slices (4 7) . The important finding is that this facili tation of the NA release is antagonized competitively by L-dopa methyl ester, while it is antagonized noncompeti tively by propranolol in rat hypothalamic slices (7) . Fur thermore, picomolar concentrations of L-dopa, which alone produce no effect, stereoselectively potentiate the isoproterenol-induced facilitation of the NA release (8). This potentiation was selectively antagonized by L-dopa methyl ester, whereas propranolol antagonized both the facilitation by isoproterenol alone and its potentiation by L-dopa. Thus, there exists a recognition site for L-dopa it self, which differs from presynaptic (3-adrenoceptors. In addition to the presynaptic actions, we recently found that L-dopa but not DA microinjected into in vivo rat nucleus tractus solitarii produced L-dopa methyl ester-sen sitive depressor and bradycardic responses (9) . These responses are not modified by pretreatment with an AADC inhibitor and with intraventricular 6-hydroxydo pamine, thereby indicating that the actions of L-dopa it self are postsynaptic in nature. All of these findings sup port the hypothesis that L-dopa is a neurotransmitter or modulator in the rat central nervous system. L-Dopa is a potentiator for presynaptic facilitatory ~3 adrenoceptors (8) . It is an important subject to study whether or not this event is universally valid for the other types of receptors. Here, we studied whether or not L dopa potentiates functions of presynaptic inhibitory a2 adrenoceptors (10) and facilitatory angiotensin II recep tors (11, 12) on noradrenergic neurons in rat hypothalam ic slices.
Experiments were done as described (8) . Briefly, the hypothalamus from Sprague-Dawley rats was cut sagittal ly, 0.3 mm in thickness. These slices were superfused at a rate of 0.45 ml/min with Krebs-Henseleit medium, kept at 37 *C and bubbled with 5% CO2 in 02, containing 113 mM NaCl, 24 mM NaHCO3, 4.75 mM KC1, 1.18 mM KH2PO4, 2.52 mM CaC12i 1.19 MM MgSO4, 11.1 MM glu cose, 0.029 mM disodium EDTA and 0.29 mM ascorbic acid. Twenty micromolar cocaine (Takeda, Osaka), an up take blocker of NA, and 20 sM 3-hydroxybenzylhydra zine (NSD-1015, Aldrich, Milwaukee, WI, USA), an AADC inhibitor, were present in the medium. Through platinum spiral electrodes at the two ends of the chamber, supramaximal electrical field stimulation (2 Hz, 2 msec, 25 V, 3 min, alternative polarity) was done twice 60 (S,) and 90 (S2) min after the start of superfusion. Samples were collected every 3 min. The evoked release (S) of NA during and after the S, and S2 stimulation periods was cal culated as the total minus the basal release for 9 min. The amount of NA in a sample immediately before stimula tion was regarded as the spontaneous release (Sp). NA in the superfusates was measured by high performance liquid chromatography with an electrochemical detector. 5-Bromo-6-[2-imidazoline-2-ylamino-quinoxaline (UK 14304, Pfizer, New York, NY, USA), a selective a2_ adrenoceptor agonist (13) , or angiotensin II (Sankyo, Tokyo) was applied without or with L-dopa 15 min before S2, and the effects were evaluated by the release ratios, S2/S, and Sp2/Sp,. Pretreatment with L-dopa methyl ester (RBI, Natick, MA, USA), a competitive L-dopa an tagonist (7); yohimbine hydrochloride (Nacalai, Kyoto), an a2-adrenoceptor antagonist; or 'Sar-8lle-angiotensin II, an angiotensin II antagonist (Daiichi Seiyaku, Tokyo), was initiated 10 min before S, and continued throughout the experiments. NA and other catecholamine contents in the tissue were measured at the end of superfusion as described (7) . Data shown are the mean ±S.E.M. Statisti cal significance was calculated by Student's t-test and one way analysis of variance. Fig. 1 . Characterization of inhibition of the release of endogenous NA from rat hypothalamic slices by UK14304 alone and its potentiation by L-dopa in the presence of NSD-1015. Field stimulation (2 Hz) was done twice at 60 (S1) and 90 (S2) min after the start of superfusion. UK14304, 10 PM L-dopa or the former with 10 PM L-dopa was applied 15 min before S2, and the effect is ex pressed as a release ratio, S2/S,, in the ordinate of (A) and in the abscissa of (B). (A) Concentration-release curves for UK14304 alone (0) and with 10 PM L-dopa (10) . Closed circle at 0 pM is 10 PM L-dopa alone. *P<0.05, **P<0.01, compared to the cor responding control at 0 pM; OP <0.05, compared to UK 14304 alone (Student's t-test). The spontaneous release and the evoked release of NA became stable 1 hr after the start of superfusion. Sp, and S, were 0.84--L 0.11 and 2.19-L0.48 fmol/mg wet wt. /min, control Sp2/Sp, and S2/S, were 0.72±0.04 and 0.87±0.03, and the tissue contents of NA and DA in slices after the superfusion experiments were 3.77±0.60 and 0.68±0.07 pmol/mg wet wt. (n=15), respectively. UK 14304 alone at 0.1-1 pM inhibited the evoked release of NA in a concentration-dependent manner (Fig. IA) . L Dopa alone at 10 pM produced no effect. The UK 14304-in duced inhibition was potentiated by 20-170% by simul taneously applied 10 PM L-dopa. L-Dopa methyl ester at 1 nM antagonized the L-dopa (10 pM)-induced potentia tion to a level of the inhibition by 0.1 pM UK 14304 alone, whereas 100 nM yohimbine antagonized both the inhibi tion by UK14304 alone and its potentiation by L-dopa to the control level (Fig. 111) .
On the other hand, angiotensin II at 0.1 and 1 nM con centration-dependently facilitated the NA release (Table  1) . This facilitation at 1 nM was completely antagonized by the pretreatment with 10 nM 'Sar-811e-angiotensin II (0.82 4:0.05, n = 4, P < 0.01, compared to 1 nM angioten sin II alone). However, this facilitation was not modified by simultaneously applied 10 PM L-dopa. Sp1, S1, Sp2/Sp1 and the tissue contents of catecholamines were not modified by the drugs used.
We have previously shown that picomolar L-dopa potentiates activities of presynaptic j3-adrenoceptors to facilitate the NA release from rat hypothalamic slices (8) . L-Dopa at 10 pM was selected as an optimum concentra tion in the present study, since the concentration-de pendent potentiation was detected at 1, 3 and 10 pM, but some decline from the maximum was seen at 30 pM (8) . These concentrations are by themselves noneffective. L Dopa similarly potentiated the inhibition of the NA re lease induced by UK 14304, an a2-adrenoceptor agonist (13) . This potentiation was selectively antagonized by L dopa methyl ester (1 nM), a competitive antagonist for the facilitatory action of L-dopa on the NA release (7). These potentiation and antagonism are probably due to the actions of L-dopa and L-dopa methyl ester themselves, since experiments were done under essentially complete in hibition (99.6070) of AADC (6) . On the other hand, yohim bine, a presynaptic a2-adrenoceptor antagonist (11) , an tagonized both the inhibition by UK14304 alone and its potentiation by L-dopa. These results suggest that L-dopa may act on the recognition site for itself, leading to the potentiation of the activities of presynaptic inhibitory a2 adrenoceptors. This potentiation of presynaptic a2 adrenoceptors by L-dopa is analogous with that for presynaptic f3-adrenoceptors in the aspect that both the ac tions were seen with picomolar L-dopa and were an tagonized by L-dopa methyl ester.
There are presynaptic facilitatory angiotensin II recep tors on noradrenergic neurons in the rat hypothalamus, since angiotensin II concentration-dependently facilitated the NA release and the facilitation was antagonized by 'Sar -811e-angiotensin II, an angiotensin II antagonist.
These results are consistent with those in rabbit hypotha lamic slices (11) and in guinea pig pulmonary arteries (12) . L-Dopa (10 pM), however, produced no effect on this angiotensin II-induced facilitation. Thus, the selec tive analogy is not seen between these facilitatory an giotensin II receptors and ~-adrenoceptors (8) in a mutual relation to the recognition site for L-dopa (7) . This finding provides evidence against an alternative proposal (14) that in some tissues, the positive feedback mechanism of the NA release via presynaptic (3-adrenoceptors may at least partially be due to ~-agonist-stimulated local an giotensin II formation and subsequent activation of presynaptic angiotensin II receptors. This was not the case in the rat hypothalamus, which is consistent with the findings in guinea pig pulmonary arteries (15) . The mutual mechanisms between L-dopa and presyna ptic j3 or a2-adrenoceptors remain to be clarified. L-Dopa may modulate a common process that is involved in a presynaptic a2 and (3-adrenoceptor-mediated signal trans duction pathway.
In conclusion, picomolar L-dopa acts on a recognition site for itself and then potentiates the activities of presynaptic a2-adrenoceptors to inhibit the release of endogenous NA from rat hypothalamic slices. 
